DUBLIN–(BUSINESS WIRE)–The “2020 Antithrombin III Testing Market: USA, Europe, Japan – Competitive Strategies, Country Forecasts, Innovative technologies and Instrumentation” report has been added to ResearchAndMarkets.com’s offering.
The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next five years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and AT III testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the AT III testing closer to the patient, creating additional opportunities and challenges for suppliers.
This report presents a detailed analysis of the AT III testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5-year test volume forecasts by country and market segment.
The report examines market applications of chromogenic substrates, monoclonal antibodies, immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
Companies Mentioned
- Abbott
- Accriva
- Axis-Shield
- Beckman Coulter/Danaher
- Becton Dickinson
- Bio/Data
- Chrono-Log
- Corgenix
- Diagnostica Stago/Trinity Biotech
- Grifols
- Helena Laboratories
- HYPHEN BioMed
- Instrumentation Laboratory/Werfen
- Roche
- Sekisui Diagnostics
- Siemens Healthineers
- Sienco
- Sysmex
- Thermo Fisher
For more information about this report visit https://www.researchandmarkets.com/r/lo4stf
